Advertisement

Uro-News

, Volume 23, Issue 2, pp 38–43 | Cite as

Medikamentöse Therapie und Forschungsstand

Das fortgeschrittene Urothelkarzinom des oberen Harntrakts

  • Nathalie GarstkaEmail author
  • Shahrokh F. Shariat
  • Axel S. Merseburger
Zertififizierte Fortbildung
  • 35 Downloads

Zusammenfassung

Das Urothelkarzinom des oberen Harntrakts ist eine seltene urologische Krebserkrankung. Aufgrund der geringen Inzidenz gibt es bislang nur wenige randomisierte klinische Studien, insbesondere im fortgeschrittenen Stadium ist die chirurgische Therapie der Goldstandard. Es werden jedoch zunehmend auch Kombinationstherapien evaluiert. Dank Genom-Isolierung und Sequenzierung bieten sich zudem mögliche neue Therapieziele auf molekularer Ebene.

Literatur

  1. 1.
    Rouprêt M et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2018; 73: 111–22CrossRefGoogle Scholar
  2. 2.
    O’Brien T et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: A prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011; 60: 703–10CrossRefGoogle Scholar
  3. 3.
    Von Rundstedt FC et al. Postoperative chemotherapy bladder instillation after nephroureterectomy: A survey from the YAU urothelial cancer group and ESOU. Eur Urol Suppl. 2018; http://doi.org/czqpGoogle Scholar
  4. 4.
    Birtle A et al. Results of POUT — a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). Eur Urol Suppl. 2018; http://doi.org/czqqGoogle Scholar
  5. 5.
    Lane BR et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer. 2010; 116: 2967–73CrossRefGoogle Scholar
  6. 6.
    Hellenthal NJ et al. Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009; 182: 900–6CrossRefGoogle Scholar
  7. 7.
    Xylinas E et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int. 2013; 112: 453–61CrossRefGoogle Scholar
  8. 8.
    Alfred Witjes J et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017; 71: 462–75CrossRefGoogle Scholar
  9. 9.
    Hanna N et al. Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial. Eur Urol Suppl. 2017; http://doi.org/czqtGoogle Scholar
  10. 10.
    Porten S et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014; 120: 1794–9CrossRefGoogle Scholar
  11. 11.
    Hoffman-Censits J et al. ECOG 8141: A prospective phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma. JCO. 2016; http://doi.org/czqsGoogle Scholar
  12. 12.
    Guarnizo E et al. Ureteroscopic biopsy of upper tract urothelial carcinoma: Improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol. 2000; 163: 52–5CrossRefGoogle Scholar
  13. 13.
    Alexandrov LB et al. Mutational Signatures and the Etiology of Human Cancers. In: Reference Module in Biomedical Sciences — Encyclopedia of Cancer. 2019; 499–510Google Scholar
  14. 14.
    Bellmunt J et al. Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). J Clin Oncol. 2018; http://doi.org/czqrGoogle Scholar
  15. 15.
    Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2017; http://doi.org/f8jn6qGoogle Scholar
  16. 16.
    Galsky M. Biological features and clinical outcomes in atezolizumab atezo treated patients pts with metastatic urothelial cancer mUC of the upper vs lower urinary tract (UTUC vs LTUC). Annals of Oncology. 2018; 29 (suppl_8): viii303–viii331CrossRefGoogle Scholar
  17. 17.
    Powles T et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncol. 2017; http://doi.org/gbsdhvGoogle Scholar
  18. 18.
    Weinstein JN et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507: 315–22CrossRefGoogle Scholar
  19. 19.
    Moss TJ et al. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017; 72: 641–9CrossRefGoogle Scholar
  20. 20.
    Sfakianos JP et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2015; 68: 970–7CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Nathalie Garstka
    • 1
    Email author
  • Shahrokh F. Shariat
    • 2
  • Axel S. Merseburger
    • 2
  1. 1.Medizinische Universität Wien, Universitätsklinik für UrologieWienDeutschland
  2. 2.

Personalised recommendations